Chromogenic In Situ Hybridization (CISH) as a Method for Detection of C-Myc Amplification in Formalin-Fixed Paraffin-Embedded Tumor Tissue: An Update

Todorović‐Raković, Nataša

doi:10.1007/978-1-0716-1476-1_17

Cited by 2 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cutoff for amplification is regarded to be the presence of more than 5 signals. The presence of 6 to 10 dots or a small cluster per nucleus in >50% of cells indicates low amplification, whereas the presence of more than 10 dots or large clusters in >50% of cells indicates high amplification 31 . Furthermore, a positive signal for EBV appears as a blue-black color over the nucleus of the cells, indicating the chromatin structure.…”

Section: Methodsmentioning

confidence: 99%

“…The presence of 6 to 10 dots or a small cluster per nucleus in > 50% of cells indicates low amplification, whereas the presence of more than 10 dots or large clusters in > 50% of cells indicates high amplification. 31 Furthermore, a positive signal for EBV appears as a blueblack color over the nucleus of the cells, indicating the chromatin structure. Variation in the staining intensity is almost usually caused by the degree of RNA preservation rather than the copy number of EBV.…”

Section: Evaluation Of Cishmentioning

confidence: 99%

See 1 more Smart Citation

Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients

Sadeghipour,

Taha,

Shariat Zadeh

et al. 2024

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults. Although studies regarding the association between the expression of Ki-67, CD10, BCL6, and MUM1 proteins, as well as c-MYC amplification and EBV status with clinicopathologic characteristics have rapidly progressed, their co-expression and prognostic role remain unsatisfactory. Therefore, this study aimed to investigate the association between the expression of all markers and clinicopathologic features and their prognostic value in DLBCL. Also, the co-expression of markers was investigated. Methods: The protein expression levels and prognostic significance of Ki-67, CD10, BCL6, and MUM1 were investigated with clinical follow-up in a total of 53 DLBCL specimens (including germinal center B [GCB] and activated B cell [ABC] subtypes) as well as adjacent normal samples using immunohistochemistry (IHC). Besides, the clinical significance and prognostic value of c-MYC and EBV status were also evaluated through chromogenic in situ hybridization (CISH), and their correlation with other markers was also assessed. Results: The results demonstrated a positive correlation between CD10 and BCL6 expression, with both markers being associated with the GCB subtype (P<0.001 and P=0.001, respectively). Besides, we observe a statistically significant association between MUM1 protein expression and clinicopathologic type (P<0.005) as well as a positive association between c-MYC and recurrence (P=0.028). Our survival analysis showed that patients who had responded to R-CHOP treatment had better overall survival (OS) and progression-free survival (PFS) than those who did not. Conclusion: Collectively, this study's results add these markers' value to the existing clinical understanding of DLBCL. However, further investigations are needed to explore markers' prognostic and biological roles in DLBCL patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Evaluation Of Cishmentioning

confidence: 99%

Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients

Sadeghipour,

Taha,

Shariat Zadeh

et al. 2024

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

show abstract

“…These methodologies diverge primarily in signal detection mechanisms and sensitivity, with fluorescent hybridization being particularly salient in brain tumor diagnosis ( 11 , 12 ). In the realm of neurobiology, the emergence of probes targeting mutations in key genes such as c-myc, EGFR, and topoisomerase IIa offers profound insights into brain tumor pathogenesis ( 13–16 ). These advancements hold promise for improving both diagnostic accuracy and treatment strategies for brain tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Hybridization techniques provide insight not only into DNA but also RNA sequences simultaneously ( 13 ). When examining mRNA, chromogenic hybridization is a common choice, utilizing dioxigenin as a marker detectable through specific peroxidases ( 37–39 ).…”

Section: Introductionmentioning

confidence: 99%

Insights into brain tumor diagnosis: exploring in situ hybridization techniques

Namiot,

Zembatov,

Tregub

2024

Front. Neurol.

View full text Add to dashboard Cite

ObjectivesDiagnosing brain tumors is critical due to their complex nature. This review explores the potential of in situ hybridization for diagnosing brain neoplasms, examining their attributes and applications in neurology and oncology.MethodsThe review surveys literature and cross-references findings with the OMIM database, examining 513 records. It pinpoints mutations suitable for in situ hybridization and identifies common chromosomal and gene anomalies in brain tumors. Emphasis is placed on mutations’ clinical implications, including prognosis and drug sensitivity.ResultsAmplifications in EGFR, MDM2, and MDM4, along with Y chromosome loss, chromosome 7 polysomy, and deletions of PTEN, CDKN2/p16, TP53, and DMBT1, correlate with poor prognosis in glioma patients. Protective genetic changes in glioma include increased expression of ADGRB3/1, IL12B, DYRKA1, VEGFC, LRRC4, and BMP4. Elevated MMP24 expression worsens prognosis in glioma, oligodendroglioma, and meningioma patients. Meningioma exhibits common chromosomal anomalies like loss of chromosomes 1, 9, 17, and 22, with specific genes implicated in their development. Main occurrences in medulloblastoma include the formation of isochromosome 17q and SHH signaling pathway disruption. Increased expression of BARHL1 is associated with prolonged survival. Adenomas mutations were reviewed with a focus on adenoma-carcinoma transition and different subtypes, with MMP9 identified as the main metalloprotease implicated in tumor progression.DiscussionMolecular-genetic diagnostics for common brain tumors involve diverse genetic anomalies. In situ hybridization shows promise for diagnosing and prognosticating tumors. Detecting tumor-specific alterations is vital for prognosis and treatment. However, many mutations require other methods, hindering in situ hybridization from becoming the primary diagnostic method.

show abstract

Chromogenic In Situ Hybridization (CISH) as a Method for Detection of C-Myc Amplification in Formalin-Fixed Paraffin-Embedded Tumor Tissue: An Update

Cited by 2 publications

References 21 publications

Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients

Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients

Insights into brain tumor diagnosis: exploring in situ hybridization techniques

Contact Info

Product

Resources

About